PeriphaGen
Dr. Wechuck is a biochemical engineer with 15 years of experience in recombinant protein production, viral vector manufacturing, and biologics testing. Prior to founding PeriphaGen Dr. Wechuck was the Senior Director of Manufacturing Development for Diamyd Incorporated and developed and advanced the proprietary cGMP manufacturing production, purification, and formulation methodologies for the Diamyd Type 1 Diabetes Drug Product and the current NET platform products. Dr. Wechuck has also led the Chemistry Manufacturing and Controls (CMC) regulatory elements for several investigational drug applications in US and Europe. Dr. Wechuck directs the development and advancement of CMC activities for PeriphaGen NET platform therapeutics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
PeriphaGen
PeriphaGen is a biopharmaceutical company focused on peripheral nerve gene therapy and committed to the development of innovative products for difficult-to-treat neurological disorders thereby improving patients' quality of life.